A
Alcista
Alcista · 25%IRWD
$0.52
Precio del escenario
$3.560
+0.061 (+1.71%)Al cierre
Loading chart…
- Máximo
- 3.590
- Apertura
- 3.530
- Precio medio ponderado por volumen
- 3.54
- Volumen
- 1.68M
- Capitalización
- 985.53M
- Mínimo
- 3.475
- Importe
- 5.95M
- EV/EBITDA, TTM
- 2.70
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Análisis de IA of Ironwood Pharmaceuticals Inc (IRWD)
VenderIronwood Pharmaceuticals is not a good buy right now due to significant negative trends. The stock has dropped 19.72% over the last 20 days and has an RSI of 32.098, indicating it is oversold. Additionally, insider selling has surged by 22659.51%, which raises concerns about the company's future direction and stability.
Recomendaciones de analistas (11)
+75.00% de potencial alcista
Comprar
5 Comprar
5 Mantener
1 Vender
Actual: 3.56
Mínimo
5.00
Promedio
6.23
Máximo
8.00
Citizens
Superar al mercado
$10
2026-02-26
Citizens
2026-02-26
Precio objetivo
$10
Superar al mercado
Craig-Hallum
Comprar
—
2026-01-05
Craig-Hallum
2026-01-05
Precio objetivo
—
Comprar
Citizens
Superar al mercado
$8
2026-01-05
Citizens
2026-01-05
Precio objetivo
$8
Superar al mercado
Wells Fargo
Equal Weight
$5
2026-01-04
Wells Fargo
2026-01-04
Precio objetivo
$5
Equal Weight
Craig-Hallum
Mantener
—
2025-11-26
Craig-Hallum
2025-11-26
Precio objetivo
—
Mantener
Métricas de valoración
El PER previsto actual de Ironwood Pharmaceuticals Inc (IRWD) es 12.33, frente a su media de 5 años de 14.77.
Escenarios de precio de Alphio AI para IRWD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IRWD en cartera
Cronología de eventos
Noticias
5.010-16NewsfilterIronwood CEO McCourt Retires, Gaskins Appointed Successor
2.008-13NASDAQ.COMIronwood (IRWD) Q2 2026 Earnings Call Transcript
5.007-14NASDAQ.COMIronwood Pharmaceuticals Appoints New CMO
8.505-29NASDAQ.COMRegulatory Approvals and Collaborations in Biotech Sector
9.005-28NASDAQ.COMFDA Approves LINZESS for Pediatric Functional Constipation Treatment
Preguntas frecuentes sobre IRWD, respondidas por Alphio AI
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ironwood Pharmaceuticals is not a good buy right now due to significant negative trends. The stock has dropped 19.72% over the last 20 days and has an RSI of 32.098, indicating it is oversold. Additionally, insider selling has surged by 22659.51%, which raises concerns about the company's future direction and stability.
11 analysts cover IRWD: 5 rate it Buy, 5 Hold and 1 Sell. The average price target is 6.23.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.